about
Resisting immune exhaustion in HIV-1 infection.Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community.Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West AfricaHIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.Molecular epidemiology of endemic human T-lymphotropic virus type 1 in a rural community in Guinea-Bissau.Immune reconstitution inflammatory syndrome and the influence of T regulatory cells: a cohort study in The Gambia.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsHIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.Ongoing queries: Interpretation of serology in asymptomatic or atypical chronic Q fever.Predicting the extinction of HIV-2 in rural Guinea-Bissau.HIV-2: the forgotten AIDS virus.Bilateral Ocular Myositis Associated with Whipple's Disease.Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.HIV-2 capsids distinguish high and low virus load patients in a West African community cohort.Ventriculitis and hydrocephalus: an unusual presentation of toxoplasmosis in an adult with human immunodeficiency virus.Significance of low positive scores obtained with a method other than acceleration in the BDProbeTec-Strand displacement amplification test for detection of Neisseria gonorrhoeae.Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia.Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic.Maternal proviral load and vertical transmission of human T cell lymphotropic virus type 1 in Guinea-Bissau.Maternal proviral load and vertical transmission of Human T cell Lymphotropic Virus type 1 in Guinea-Bissau.Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection.Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines.HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation.Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau.Cutaneous leishmaniasis acquired during a brief visit to Cyprus.Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia.Value of immunogenicity studies of influenza vaccine in resource-limited settings.Potential impact of influenza vaccine roll-out on antibiotic use in Africa.Molecular epidemiology of endemic Human T-Lymphotropic virus 1 (HTLV-1) in a community in rural Guinea-Bissau.T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cellsEffect of HIV-2 Infection on HIV-1 Disease ProgressionSociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief modeRoutine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmesHaemorrhagic acute disseminated encephalomyelitis: an unusual case of blindness in an HIV-infected patientThe efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic reviewA comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoieComplexities in predicting the immunogenicity of live attenuated influenza vaccines
P50
Q33332291-9C941133-AB30-499B-9F83-6DB4CC4C9965Q33955745-32D950E3-C947-4664-99D5-B699C790FA24Q34110662-17C2E2A4-6211-4D7F-83F5-5244433BA891Q34111234-0F02840A-0790-42A6-B083-3EBA6FE24E81Q34243456-14D05E44-7F32-432E-AA24-CD8F3D899A6DQ34312423-BC72911E-8DB1-4393-882D-58E148E1AD94Q34321256-A9F7BF06-0F47-4519-B44A-EB603724F7B8Q34730950-DFBBCD7F-A4CC-4DDA-A6FF-4C6E90415872Q35008562-F8379255-15A6-4261-A766-3E61EB4901D2Q35223805-5F729562-6FD8-4D20-A7DF-A8809FC3AC37Q35665765-40580B7A-A6A5-4A42-A1EA-3A58712717BDQ36242457-1DC5F7A3-9D32-4A0D-B40D-D78413A8242FQ36282706-3AD4B7C0-8F3D-4569-97C1-A0E97C271BEAQ37311971-47C51494-B7D1-404D-AE79-C537135E780BQ37654992-5888F570-9396-4817-8B7E-3BABB2A7BFADQ39251542-A1814EC9-C486-42B5-92BB-68250B320669Q43050851-87FF6931-A3C5-4B48-ACE0-D00690C24859Q43067606-C2A95151-3B5A-4E8E-A80F-48688269AE69Q43124624-6CC2F847-6BA5-47C7-97F5-3B36C2F92CDCQ43594543-21CBAC5E-1154-40EA-9EBA-E97EC8FBB83AQ44896855-730E08FC-99D4-42DA-A804-3145796C2C22Q45361897-02292B85-957D-435D-8AFE-B1ABE08A0663Q45785238-F63C42E0-7C3B-4284-9C3A-DE03E1822FAFQ46456404-9A68CAD9-4BD8-4A3F-87D5-C7321F145228Q46758392-FD7A9EDB-126C-4AC7-80D7-2F4D0E783573Q47549002-64D4EFA9-31AC-435E-9B16-ACDAA7BDDB52Q48069969-466E4658-8066-4EA1-88CA-83D3F79D813EQ50444729-D47742F7-88D8-4DCF-9201-72193225A6AEQ52684550-5368165C-A25A-4606-886C-459E23803382Q53738692-185244F3-480F-4E66-AE23-FC12CC3C58D6Q54215595-325D0DCD-197A-43B8-8B75-98F8182DAB2EQ55622815-2B7A0801-88BD-448E-8A82-68C068FC5356Q57259563-B7EE0B20-BA9B-43B5-A786-A4A904A1EF9BQ57450115-D4C81029-4D0C-4D55-A290-2D3EAC69A71AQ58795571-BF7DB7C8-E01B-4CA6-9091-EAC0115B06DAQ59402113-FD835252-9DFF-4FBC-9409-532698EC289BQ59402159-49128005-1877-440D-8757-F546C8607D44Q90554409-50767D8D-B0E7-4808-9974-34B3412B57FBQ90566983-2A520718-B58C-41D0-AA7D-5630A8986A4DQ92616940-2A60E2EB-1AEF-4761-A930-12CCBEEDABBB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thushan I de Silva
@ast
Thushan I de Silva
@en
Thushan I de Silva
@es
Thushan I de Silva
@nl
type
label
Thushan I de Silva
@ast
Thushan I de Silva
@en
Thushan I de Silva
@es
Thushan I de Silva
@nl
prefLabel
Thushan I de Silva
@ast
Thushan I de Silva
@en
Thushan I de Silva
@es
Thushan I de Silva
@nl
P106
P31
P496
0000-0002-6498-9212